Agios Pharmaceuticals Inc (NASDAQ:AGIO) – Stock analysts at Oppenheimer decreased their FY2022 earnings estimates for Agios Pharmaceuticals in a report released on Thursday, August 2nd. Oppenheimer analyst L. Cann now forecasts that the biopharmaceutical company will earn $4.06 per share for the year, down from their prior estimate of $4.12.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($1.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.62) by $0.43. Agios Pharmaceuticals had a negative return on equity of 51.71% and a negative net margin of 462.08%. The company had revenue of $40.40 million for the quarter, compared to the consensus estimate of $12.47 million. During the same period in the previous year, the business earned ($1.78) EPS. The firm’s revenue was up 257.5% compared to the same quarter last year.

A number of other analysts have also commented on the company. Needham & Company LLC reaffirmed a “buy” rating on shares of Agios Pharmaceuticals in a research report on Thursday, August 2nd. Canaccord Genuity reaffirmed a “buy” rating on shares of Agios Pharmaceuticals in a research report on Thursday, August 2nd. Piper Jaffray Companies set a $125.00 target price on Agios Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, August 2nd. SunTrust Banks reaffirmed a “buy” rating and issued a $123.00 target price on shares of Agios Pharmaceuticals in a research report on Monday, July 23rd. Finally, Cann reaffirmed a “hold” rating on shares of Agios Pharmaceuticals in a research report on Friday, July 20th. Four research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. Agios Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $97.90.

Agios Pharmaceuticals traded down $1.81, reaching $78.55, during midday trading on Monday, Marketbeat Ratings reports. The stock had a trading volume of 10,625 shares, compared to its average volume of 359,345. Agios Pharmaceuticals has a 12 month low of $51.62 and a 12 month high of $99.82. The firm has a market capitalization of $4.58 billion, a price-to-earnings ratio of -11.84 and a beta of 1.97.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Strs Ohio purchased a new position in shares of Agios Pharmaceuticals in the 2nd quarter worth approximately $179,000. NewSquare Capital LLC purchased a new position in shares of Agios Pharmaceuticals in the 2nd quarter worth approximately $182,000. Barrett Asset Management LLC purchased a new position in shares of Agios Pharmaceuticals in the 2nd quarter worth approximately $253,000. Xact Kapitalforvaltning AB purchased a new position in shares of Agios Pharmaceuticals in the 4th quarter worth approximately $259,000. Finally, S&CO Inc. purchased a new position in shares of Agios Pharmaceuticals in the 1st quarter worth approximately $278,000. 95.10% of the stock is owned by hedge funds and other institutional investors.

In other Agios Pharmaceuticals news, insider Steven L. Hoerter sold 2,050 shares of the business’s stock in a transaction that occurred on Friday, June 22nd. The stock was sold at an average price of $97.58, for a total transaction of $200,039.00. Following the completion of the sale, the insider now directly owns 2,050 shares of the company’s stock, valued at approximately $200,039. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Christopher Bowden sold 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 12th. The stock was sold at an average price of $92.89, for a total value of $185,780.00. The disclosure for this sale can be found here. Insiders have sold a total of 144,549 shares of company stock valued at $13,133,295 over the last three months. Corporate insiders own 3.02% of the company’s stock.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.

Featured Story: Stock Symbols, CUSIP and Other Stock Identifiers

Earnings History and Estimates for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.